Dosing Reliability of Direct Thrombin Inhibitors in Extracorporeal Membrane Oxygenation: A Systematic Review and...

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Extracorporeal membrane oxygenation (ECMO) requires anticoagulation, with heparin being standard.
• Direct thrombin inhibitors (DTIs) are proposed to offer superior hemostasis compared to heparin during ECMO.
• Mechanisms underlying DTI efficacy in ECMO patients remain unclear.

Purpose of the Study:

• To systematically compare the efficacy of DTIs versus heparin in patients undergoing ECMO.
• To elucidate the specific anticoagulation parameters influenced by DTIs in ECMO support.

Main Methods:

• Systematic literature search of databases and registers for comparative studies.
• Random-effects meta-analysis of 28 identified studies (25 bivalirudin, 3 argatroban).
• Subgroup and sensitivity analyses to assess robustness and specific DTI effects.

Main Results:

• DTIs significantly reduced time to achieve therapeutic anticoagulation (MD = -6.96 hours) compared to heparin.
• DTIs maintained the therapeutic anticoagulation range for a greater proportion of time (MD = 18.6%).
• Bivalirudin demonstrated significant benefits in adults; effects were not significant in pediatric patients or with argatroban.

Conclusions:

• Direct thrombin inhibitors, particularly bivalirudin, offer improved anticoagulation control during ECMO compared to heparin.
• Faster achievement and longer maintenance of therapeutic anticoagulation suggest potential clinical advantages for DTIs in ECMO.
• Further research may be warranted to clarify DTI efficacy in pediatric ECMO and with argatroban.